Clinical Trials
0
0 active
Approvals
20
Total approvals
Agencies
1
Regulatory bodies
Founded
N/A
No trial phase data available
No trial data available
No trial data available
- Strides Pharma has received FDA approval for its generic Fluoxetine 60mg tablets, expanding its portfolio of this antidepressant drug. - The approval allows Strides Pharma to offer a complete range of Fluoxetine products, including 10mg, 20mg, and 60mg tablets and capsules. - Fluoxetine capsules and tablets have a combined market size of $130 million, offering a substantial commercial opportunity for Strides Pharma. - Strides Pharma plans to launch all three strengths of Fluoxetine tablets in the near future, manufactured at its facility in Puducherry.
- Strides Pharma's subsidiary secures USFDA approval for generic Theophylline extended-release tablets, used for chronic asthma and lung diseases. - The approved drug, a generic version of Theo-Dur, addresses symptoms like wheezing and shortness of breath by relaxing bronchial muscles. - Theophylline extended-release tablets, with a market size of $11.5 million, will be manufactured in Bangalore, enhancing Strides Pharma's portfolio. - Strides Pharma's stock price surged following the announcement, reflecting investor confidence in the company's growth and market position.
